SEC23B

Across TCGA pan-cancer cohorts, SEC23B RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SEC23B’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SEC23B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SEC23B is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

BLCA, COAD, and STAD are the cancer types where SEC23B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SEC23B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	+1.472	<.001	11	view →
COAD	All	III,IV	+0.875	<.001	11	view →
STAD	All	II,III,IV	+1.222	<.001	8	view →
LIHC	All	II,III,IV	+1.060	<.001	8	view →
THCA	Male	III,IV	−0.991	<.001	8	view →
BRCA	All	III,IV	+1.010	<.001	6	view →
READ	All	II,III,IV	+0.870	.010	6	view →
CHOL	Male	All	+2.245	<.001	5	view →
KICH	All	All	−0.633	.001	5	view →
UCEC	All	III,IV	+1.108	.009	4	view →
HNSC	All	All	+0.360	.018	4	view →
LUAD	All	All	+0.248	.007	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SEC23B–BLCA

Open the BLCA breakdown →